The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

27 November 2014
london-big

John Andrews, consultant editor of The Economist, opened the Global Crisis of Depression conference in London on Tuesday by citing the 92 billion-euro ($115 billion) annual cost of the disease to Europe - this is the magnitude of the crisis contemporary society is dealing with.

It is the leading global cause of disability, and special address speaker, former UN Secretary General Kofi Annan, said “calling the challenge of depression a ‘global crisis’ is no exaggeration at all.” He spoke of the major gap between provisions for physical health care in developed countries, and the frequent lack of any mental health care framework in developing countries. “Treating depression in primary care is affordable and cost-effective,” he said.

Norman Lamb, Minister for Care and Support at the UK's Department of Health, in his address on the political imperatives to address mental health and depression, said: “We are held back by an imbalance in the payment system,” and referenced the “institutional bias” against mental health. Patients, he said, can see a cancer specialist within two weeks in the UK but no such guarantees exist for patients with mental health diagnoses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical